Asterand has announced the addition of Good Laboratory Practice (GLP) compliant molecular pathology services supporting preclinical safety studies to its Phasezero services platform.
The company's first new service offering will be tissue cross reactivity testing for therapeutic antibodies in order to supply clients with critical data required by regulatory authorities, such as the Food and Drug Administration and European Medicines Agency, for investigational new drug submissions.
Acceptance as a member of the UK GLP Compliance Monitoring Programme will also allow Asterand to expand its offering of GLP-compliant preclinical services to its pharmaceutical and biotech clients.
